New hope for tough leukemia: testing a powerful drug trio in kids and young adults
NCT ID NCT06863259
Summary
This early-stage trial is testing whether a combination of three drugs—Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone (called IoVeX)—is safe and tolerable for children and young adults (ages 1-39) whose B-cell acute lymphoblastic leukemia (B-ALL) has returned after prior treatment. The main goal is to identify any medical problems or side effects patients experience while taking these drugs. Participants will receive the drug combination in 28-day cycles, with close monitoring through checkups and tests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
Conditions
Explore the condition pages connected to this study.